• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Luke Greenwalt of IQVIA on Obesity Drug Market | Asembia 2024


In an interview before the Asembia meeting, Luke Greenwalt, MBA, vice president, market access for IQVIA, discussed the hot topic of the meeting — GLP-1s and the obesity market.

"Over the next five years we are going to see this space get super intense. We are going to see a lot of products comes in," Greenwalt said.

IQVIA is tracking 100 new possible drugs for obesity in development and that the global market could reach $100 billion, he said.

The obesity drugs could lead to more diagnoses of obesity-related health conditions and therefore more prescriptions to treat those conditions, Geenwalt added.

Over the long run, though, he noted the the GLP-1s and other obesity-related drugs could lessen demand for those treatments if people lose weight and therefore experience fewer diseases caused by obesity and being overweight.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.